Table 1

Summary of family studies with MGUS and MM probands

ReferenceStudy typePopulation detailsNo. of probandsNo. of relatives of probandsNo. of affected relativesRisk of MGUS or MM (95% CI)
MGUS probands       
    Steingrímsdóttir et al11 * Registry-based family study Iceland 16 with either MGUS or MM (2 in each family) 4370 total; 350 first-degree 31 (22 identified by registry, 9 by screening)  
    Landgren et al Population-based case-control study Sweden 4458 (matched with 17 505 controls) 14 621 (58 387 relatives of controls) 22 MGUS/41 MM (vs 31 MGUS/57 MM in controls) RR = 2.8 (1.4-5.6)/2.9 (1.9-4.3)§ 
    Vachon et al  Population-based prevalence study United States (Olmsted County, white) 97 MGUS/232 MM 247 MGUS relatives/664 MM relatives 30 of MGUS cases/53 of MM cases RR = 3.3 (2.1-4.8)/2.0 (1.4-2.8)§ 
    Jain et al12  Family case study United States (black) 10 2 MM  
    Lynch et al13  Family case study United States (black) 11 3 MGUS with abnormal FLC ratios; (5 MM previously identified)  
Multiple myeloma probands       
    Kristinsson et al14  Registry-based case-control study Sweden 13 896 (matched with 54 365 controls) 37 838 (151,068 relatives of controls) 42 MGUS/94 MM RR = 2.1 (1.5-3.1)/2.1 (1.6-2.9)§ 
    Hemminki et al15  Family study Sweden 23 parents with MM (of 754 165 parents)  23 familial cases (878 sporadic) in offspring SIR = 3.33 (2.1-5.0)§ 
    Brown et al Case-control United States (blacks and whites) 565 (2104 controls)   OR = 3.7 (1.2-12.0)§ 
    Grosbois et al16  Registry-based family study 104 Intergroupe Francophone du Myelome centers 15 25 15  
    Eriksson et al17  Case-control Sweden 239 (220 matched controls) NA NA RR = 2.36 (0.90-6.15) 
    Bourguet et al Case-control Duke University Medical Center 439 (1317 matched controls) NA 3 (4 in controls) RR = 2.4 (1.4-4.0)§ 
ReferenceStudy typePopulation detailsNo. of probandsNo. of relatives of probandsNo. of affected relativesRisk of MGUS or MM (95% CI)
MGUS probands       
    Steingrímsdóttir et al11 * Registry-based family study Iceland 16 with either MGUS or MM (2 in each family) 4370 total; 350 first-degree 31 (22 identified by registry, 9 by screening)  
    Landgren et al Population-based case-control study Sweden 4458 (matched with 17 505 controls) 14 621 (58 387 relatives of controls) 22 MGUS/41 MM (vs 31 MGUS/57 MM in controls) RR = 2.8 (1.4-5.6)/2.9 (1.9-4.3)§ 
    Vachon et al  Population-based prevalence study United States (Olmsted County, white) 97 MGUS/232 MM 247 MGUS relatives/664 MM relatives 30 of MGUS cases/53 of MM cases RR = 3.3 (2.1-4.8)/2.0 (1.4-2.8)§ 
    Jain et al12  Family case study United States (black) 10 2 MM  
    Lynch et al13  Family case study United States (black) 11 3 MGUS with abnormal FLC ratios; (5 MM previously identified)  
Multiple myeloma probands       
    Kristinsson et al14  Registry-based case-control study Sweden 13 896 (matched with 54 365 controls) 37 838 (151,068 relatives of controls) 42 MGUS/94 MM RR = 2.1 (1.5-3.1)/2.1 (1.6-2.9)§ 
    Hemminki et al15  Family study Sweden 23 parents with MM (of 754 165 parents)  23 familial cases (878 sporadic) in offspring SIR = 3.33 (2.1-5.0)§ 
    Brown et al Case-control United States (blacks and whites) 565 (2104 controls)   OR = 3.7 (1.2-12.0)§ 
    Grosbois et al16  Registry-based family study 104 Intergroupe Francophone du Myelome centers 15 25 15  
    Eriksson et al17  Case-control Sweden 239 (220 matched controls) NA NA RR = 2.36 (0.90-6.15) 
    Bourguet et al Case-control Duke University Medical Center 439 (1317 matched controls) NA 3 (4 in controls) RR = 2.4 (1.4-4.0)§ 

SIR indicates standardized incidence ratio; and NA, not available.

*

Also included WM and MM myeloma cases in probands.

MGUS families only.

Risk of MGUS listed, followed by risk of MM, if any given.

§

Risk of developing multiple myeloma.

Risk of all hematologic malignancies.

Close Modal

or Create an Account

Close Modal
Close Modal